
Interim phase 3 results showed darolutamide cut metastasis-or-death risk by 58%, while approval for early-stage use remains outstanding.
Bayer shares rose after the company reported positive interim results for Nubeqa in early prostate cancer. In a phase 3 study, darolutamide combined with standard therapy reduced the risk of metastasis or death by 58% versus placebo in patients at high risk of relapse.
After four years, 95% of patients receiving the drug were metastasis-free, compared with 88% in the placebo group. Nubeqa is approved for more advanced prostate cancer, but approval for the early treatment stage studied has not yet been granted.
Bayer shares rose about 3% shortly after Monday’s market open, according to the report. As of 08:57 UTC on Monday, the stock traded at €45.16, up 2.68% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.